Use of rivastigmine

PheWeb

ADMED_ACHEI_RIVASTIGMINE

No definition available.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Medicine purchases: ATC N06DA03

2880

Check pre-conditions, main-only, mode, ICD version None

2373

Check minimum number of events

Min. number of events 3

2373

Include endpoints None

2373

ADMED_ACHEI_RIVASTIGMINE

Extra metadata

First used in FinnGen datafreeze DF2

Similar endpoints

↥

List of similar endpoints to Use of rivastigmine based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	2296	1072	1224
Unadjusted prevalence (%)	0.74	0.62	0.91
Mean age at first event (years)	77.84	78.61	77.16

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: ADMED_ACHEI_RIVASTIGMINE – Use of rivastigmine
GWS hits:

Survival analyses between endpoints

↥

Plot

before Use of rivastigmine
after Use of rivastigmine

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Use of rivastigmine

↥